gsk201501276k.htm
FORM 6-K/A
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
athe Securities Exchange Act of 1934
For period ending January 2015
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc (the "Company")
Board Committee changes
GSK announces that Sir Philip Hampton has been appointed Chairman of the Nominations Committee (the "Committee") with effect from today, replacing Sir Christopher Gent, who will continue to serve as a member of the Committee for the remainder of his tenure on the Board.
In addition, Ms Lynn Elsenhans has also been appointed a member of the Committee, effective today.
The membership of the Nominations Committee is now:
|
Committee Chairman
|
Sir Philip Hampton
|
Chairman Designate
|
|
Members
|
Sir Christopher Gent
|
Chairman
|
| |
Professor Sir Roy Anderson
|
Scientific & Medical Expert
|
| |
Lynn Elsenhans
|
Independent Non Executive Director
|
| |
Judy Lewent
|
Audit & Risk Committee Chairman
|
| |
Sir Deryck Maughan
|
Senior Independent Director
|
| |
Tom de Swaan
|
Remuneration Committee Chairman
|
V A Whyte
Company Secretary
27 January 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: January 27, 2015
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc